Aerogen Collaborates on Development of More Than 15 Potential COVID-19 Inhaled Therapies

Aerogen recently announced details of a broad collaborative effort to support pharmaceutical companies from around the world as they work to develop COVID-19 vaccines and treatments. To date, more than 10 million patients globally have been treated safely and effectively with Aerogen’s drug delivery technology. As the global scientific community rallies against the pandemic, there has been unprecedented interest in inhaled delivery of antiviral drugs, leading to Aerogen’s involvement in multiple COVID-19 drug development initiatives with leading pharmaceutical companies and prominent academic groups.

Aerogen’s closed-circuit nebulizer technology, which addresses key concerns around safety and improves patient outcomes, is being used in hospitals across the globe to deliver aerosolized medication to critically ill ventilated COVID-19 patients. Aerogen was quick to anticipate the critical role that development of new inhaled drugs will ultimately play in the COVID-19 response, and in March of this year, formed a COVID response unit to support projects researching potential treatments and vaccines. This response unit is now working with pharmaceutical companies worldwide to ensure safe delivery of inhaled therapies. Several of these collaborations are already in clinical trials, with others on track to enter studies on moderately and severely ill COVID-19 patients over the weeks and months ahead.

In one such collaboration, Aerogen has signed an agreement with Synairgen plc, a Southampton, UK-based biotechnology company, to provide the market-leading Aerogen Solo/Ultra nebulizer system for delivery of SNG001 directly into the lungs of COVID-19 patients. SNG001 is an inhaled interferon beta that stimulates the innate immune system. Initial investigation of SNG001 as a potential COVID-19 treatment has been promising – hospitalized patients receiving SNG001 were at reduced risk of developing severe disease and more than twice as likely to recover to the “no limitation of activities” level on the ordinal scale over the course of treatment.

“Aerogen is a highly regarded global company known for providing safe and effective aerosol drug delivery,” said Richard Marsden, CEO of Synairgen. “Ensuring that SGN001 is paired with optimal delivery technology is a vital component of our work to bring this potential treatment to market at scale. Aerogen is our choice because of its proven reputation for drug delivery efficiency and reliability, suitability for use with a wide range of ventilatory support modalities, established high-volume manufacturing and prior regulatory approvals across the globe.”

“In the early days of the pandemic, hospitals were discouraged from using any type of aerosol for COVID-19 treatment – which is understandable given the nature of the virus,” said John Power, CEO and Founder of Aerogen. “Now, it’s clear to health systems worldwide that aerosol drug delivery can be done with improved safety but is an absolute necessity for managing this global crisis. COVID-19 has only reinforced the important role Aerogen plays in safely and effectively delivering treatments to patients across the world, and we’re proud to work with innovators like Synairgen as part of the research and development process for potential COVID-19 vaccines and treatments.”

The Aerogen Solo is a closed-system, single-patient use (vibrating mesh) aerosol drug delivery technology offering superior performance across all hospital ventilation modalities. Designed for the safety of both the patient and the caregiver, Aerogen’s closed-circuit design enables the only global aerosol drug delivery system which mitigates the transmission of patient-generated infectious aerosol during ventilation. Aerogen is committed to working with pharmaceutical companies worldwide to meet the current global demand for inhaled delivery of antiviral drugs and offers industry-leading expertise and technology in combination with a proven track record in the development of inhalation therapeutics. For more information, visit visit www.aerogen.com/products.  For more information on Aerogen’s role in the fight against COVID-19, visit www.aerogen.com/covid-19.

Aerogen is the world’s leading medical device company specializing in the design, manufacture, and commercialization of aerosol drug delivery systems.  Aerogen’s patented vibrating mesh technology turns liquid medication into a fine particle mist, gently and effectively delivering drugs to the lungs of patients.  Aerogen’s innovative products, such as the Aerogen Solo and Aerogen Ultra, significantly improve aerosol drug delivery, resulting in better patient care throughout the Hospital across all ages.  Founded in Galway, Ireland, in 1997, Aerogen has grown to become the global leader in high performance aerosol drug delivery and has partnered its technology with the leading mechanical ventilation companies.  Aerogen technology is used by millions of patients and caregivers in over 75 countries worldwide.